This site is intended for health professionals only!

Published on 17 September 2009

Share this story:
Twitter
LinkedIn

Bayer announces new data on oncology portfolio

teaser

Bayer Schering Pharma today announced that data from more than 30 clinical trials evaluating three products in the company’s oncology portfolio – Nexavar (sorafenib) tablets, regorafenib (BAY 73-4506) and Alpharadin – will be presented at the joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress, September 20-24, 2009 in Berlin, Germany.

“Bayer is committed to discovering and developing innovative
cancer-fighting therapies, and as a global organisation with widespread reach and impact, we are able to apply our experience, knowledge and passion to offer treatments that may make life better for cancer patients across the globe,” said Rob Rosen, Head of the Therapeutic Area Oncology at Bayer Schering Pharma.

“While much progress has been made in the treatment of cancer, there is still an unmet medical need for improved therapies that may help patients manage their disease, ultimately treating cancer as a chronic illness, rather than a devastating disease.”

Nexavar Data Highlights
Nexavar is currently approved in more than 80 countries for the
treatment of patients with hepatocellular carcinoma (HCC), or liver cancer, and in more than 90 countries for the treatment of patients with advanced renal cell carcinoma (RCC), or kidney cancer. Even though these indications are well established, the utility of Nexavar continues to be evaluated in these tumor types, with ongoing studies examining special patient populations and long-term use. Data on these indications being presented at ECCO-ESMO include results from two Phase III studies evaluating Nexavar in HCC and six studies examining Nexavar in RCC.

In addition to its current indications, Nexavar continues to be
evaluated as a single agent or combination treatment in a wide range of cancers, including breast cancer, thyroid cancer, and as an adjuvant therapy for kidney cancer and liver cancer. Data from a recently unblinded phase II trial evaluating the safety and efficacy of Nexavar as a potential treatment for breast cancer will be presented during an oral session at ECCO-ESMO. This trial examined Nexavar compared to placebo in combination with the oral chemotherapeutic agent, capecitabine, in patients with locally advanced or metastatic breast cancer.

To find out more, please click on the link below:

Bayer Schering



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn